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MEDICAID DRUG SPENDING AFTER THE MEDICARE
MODERNIZATION ACT: WHAT WILL BE LEFT?
Boulanger L, Brown J, Menzin J
Boston Health Economics, Inc, Waltham, MA, USA
OBJECTIVES: To evaluate drug expenditures among Medicaid
recipients who are not also Medicare eligible and therefore
whose costs will still be paid by Medicaid following implemen-
tation of the Medicare Modernization Act (MMA). METHODS:
We analyzed 2002 pharmacy claims data and eligibility records
from a 20% random sample of California Medicaid (“Medi-
Cal”) recipients. The number of unique patients, prescriptions
dispensed, units dispensed, and Medicaid paid amounts were
obtained for each class of pharmaceuticals. Patients were con-
sidered dually eligible if they were eligible for Medicare and
Medicaid coverage for at least one month in 2002. Medicaid
payments, excluding rebates, were projected to the entire Medi-
Cal program. For simplicity, we report ﬁndings from the top ten
drug classes in terms of total Medicaid projected payments and
the percentage paid for non-dually eligible recipients. RESULTS:
We estimated that California Medicaid spent approximately
$1.98 billion for the top ten classes of drugs. These classes rep-
resented approximately 53% of total Medi-Cal drug expendi-
tures in 2002. Forty-three percent of these payments were for
recipients who were not dually eligible for Medicare and Med-
icaid. The top ten classes in terms of expenditures were (with
amount paid and percent paid for non-dually eligible recipients
in parentheses): antipsychotics ($530 million, 55%), gastro-
intestinal drugs ($228 million, 32%), antidepressants ($220
million, 50%), antivirals ($191 million, 49%), antihyperlipi-
demics ($172 million, 27%), NSAIDs ($162 million, 33%), anti-
convulsants ($142 million, 53%), antidiabetics ($122 million,
32%), calcium channel blockers ($113 million, 24%), and opiate
agonists ($96 million, 43%). CONCLUSION: The California
Medicaid program will remain responsible for a substantial
portion of drug spending for central nervous system disorders
following implementation of the MMA, but the cost burden for
cardiovascular medications will be lowered greatly.
HP2
EFFECTS OF PATIENTS’ BELIEFS ABOUT MEDICATIONS ON
NON-ADHERENCE TO CHRONIC MEDICATIONS
Phatak HM,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Non-adherence to medications is a major
problem among patients using chronic medications. Patients’
medication beliefs are among modiﬁable factors considered to
inﬂuence non-adherence. The primary aim of this study was to
investigate associations between patients’ beliefs about medica-
tions and non-adherence to chronic medications. METHODS: A
cross-sectional self-administered survey was conducted of
patients visiting a primary care clinic. Participants’ medication
beliefs and medication non-adherence were assessed using the
Beliefs about Medications Questionnaire as developed by Horne
et al. and the Morisky Medication Adherence Scale. Sociode-
mographic and clinical information also were collected. 
Spearman correlation analyses were used to assess associations
between medication beliefs and medication non-adherence.
RESULTS: A total of 443 patients were approached and 314 met
study criteria of using at least one chronic medication for more
than 2 months and ability to speak English. Of the 314 patients
meeting inclusion criteria, 250 agreed to complete the survey, a
response rate of 79.6%. Most of the participants (62.25%) were
between 30 and 49 years old. Whites constituted 53% and blacks
constituted 40% of the sample. Participants had a mean of 3.2
conditions (±2.1) and used a mean of 5.3 medications (±4.1).
Participants perceiving less necessity to use medications (r =
-0.2, p = 0.005) and with higher concerns about medications 
(r = 0.4, p < 0.0001) had higher non-adherence to medications.
Participants perceiving higher general harmful effects of med-
ications (r = 0.3, p < 0.0001) and with higher perceptions of
over-prescribing of medications by physicians (r = 0.3, p <
0.0001) had higher non-adherence to medications. Medication
beliefs predicted 22% of variation in non-adherence to chronic
medications. CONCLUSION: There were signiﬁcant associa-
tions between medication beliefs and non-adherence. Health care
providers may help patients improve their adherence to medica-
tions by resolving issues identiﬁed through medication beliefs
assessment.
HP3
WHO WILL REQUEST A SWITCH TO NEW TREATMENT AS A
RESULT OF DIRECT-TO-CONSUMER ADVERTISING?
Chen HD, Carroll N
Virginia Commonwealth University, Richmond,VA, USA
OBJECTIVES: To identify the factors that inﬂuence consumers
to request a switch to new treatment as a result of Direct-
to-Consumer (DTC) advertising. METHODS: Data were taken
from a national survey, “Public Health Impact of Direct-to-
Consumer Advertising of Prescription Drugs, July 2001–January
2002”, conducted by researchers from Harvard Medical School.
Participants (n = 3000) were interviewed by telephone. We con-
structed a conceptual framework consisting of outcome (switch-
ing request), intervention (DTC experience) and ﬁve groups of
explanatory factors (health beliefs, demographics, health status,
socioeconomic status and market factors). Data were analyzed
with multivariate stepwise logistic regression. The dependent
variable was whether a DTC advertisement for a prescription
drug had ever prompted the patient to ask for a change to 
new treatment for a medical condition or illness. RESULTS:
Health beliefs were strong predictors of switching request.
Patients who regarded media as the most important referent
source were more likely to make requests than those who did
not. (OR, 4.8; 95%CI, 3.42–6.71). Believing that DTC adver-
Volume 8 • Number 3 • 2005
V A L U E  I N  H E A L T H
ISPOR Tenth Annual International Meeting
Contributed Presentation Abstracts
Contributed Podium Presentations
© ISPOR 1098-3015/05/237 237–257
238 Abstracts
tisements increased awareness of new treatment (perceived
beneﬁt) and improved discussion with health professionals (per-
ceived beneﬁt) were both positively associated with switching
request (p = 0.001 and p < 0.0001, respectively). Believing that
DTC advertisements led to decreased conﬁdence in doctor’s judg-
ment (perceived barrier) was negatively associated with switch-
ing request (p = 0.02). Patients on regular medication (OR, 
2.03; 95% CI, 1.48–2.78), black patients (OR, 2.76; 95% CI,
1.48–5.13), patients with higher attentiveness to DTC advertis-
ing (p < 0.0001), and patients with allergies (OR, 1.35; 95% CI,
1.01–1.79), asthma (OR, 1.71; 95% CI, 1.09–4.33), or anxiety
(OR, 1.60; 95% CI, 1.23–2.57), were more likely to make
switching requests. CONCLUSIONS: Patients’ switching
requests were associated with health beliefs, race, health status,
and attentiveness to DTC advertising.
HP4
POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING
FOR ELDERLY AMBULATORY PATIENTS IN REGIONE EMILIA
ROMAGNA, ITALY
Maio V,Yuen EJ, Novielli KD, Rabinowitz C, Louis DZ
Jefferson Medical College, Philadelphia, PA, USA
OBJECTIVES: To investigate the prevalence of potentially inap-
propriate medication prescribing (PIP) among elderly residents
in Regione Emilia Romagna (RER), Italy and to examine factors
associated with having PIP. METHODS: We conducted a retro-
spective cohort study using the 2001 outpatient prescription
claims RER database. We linked individuals in this database with
information (age, gender, and other variables) available from a
demographic ﬁle of approximately 1 million elderly RER resi-
dents. The cohort comprised 849,425 subjects 65 years or older,
who had at least one drug prescription during the study period.
PIP was deﬁned as having a prescription claim for a medication
included in the 2003 Beers updated list of drugs to be avoided
in the elderly. Of the 48 medications in the list, 19 were reim-
bursed in 2001 by the Italian National Formulary and included
in the analysis. RESULTS: A total of 152,641 elderly in the
cohort (18.0%) had 1 or more occurrences of PIP. Of these,
11.5% received prescriptions for 2 medications of concern and
1.7% for 3 or more. Doxazosin (23.0% of the subjects) was the
most frequently occurring PIP, followed by ketorolac (20.5%),
ticlopidine (18.3%), and amiodarone (12.6%). More than half
of the PIP was for drugs with the potential for severe adverse
outcomes. Factors associated with greater likelihood of PIP were
male, older age, overall number of drugs prescribed, greater
number of chronic conditions, and lower income level. CON-
CLUSIONS: This study provides strong evidence that PIP for
elderly ambulatory patients is a substantial problem in Italy.
Because we were able to analyze only a fraction of the Beers’
drugs list, our results underestimate the extent of PIP. The aware-
ness of the prevalence of PIP and associated determinants may
be useful in designing and implementing effective programs 
targeting outpatient practitioners to inﬂuence their prescribing
behavior to reduce PIP.
Cancer
CN1
COST-EFFECTIVENESS OF ONCE WEEKLY EPOETIN ALFA
AND DARBEPOETIN ALFA IN TREATING CHEMOTHERAPY-
INDUCED ANEMIA
Ben-Hamadi R1, Duh MS1,Aggarwal J1, Henckler A1, McKenzie S2,
Fastenau J3, Piech CT3
1Analysis Group Inc, Boston, MA, USA; 2Ortho Biotech Clinical Affairs
LLC, Dallas,TX, USA; 3Ortho Biotech Clinical Affairs LLC,
Bridgewater, NJ, USA
OBJECTIVES: To analyze the comparative cost effectiveness of
epoetin alfa (EPO) and darbepoetin alfa (DARB) based on the
FDA-approved doses for EPO (40,000 Units/week) and DARB
(2.25mcg/kg/week) for the treatment of chemotherapy-induced
anemia (CIA). METHODS: Clinical results were drawn from
two randomized, double blind, placebo-controlled phase III 
registration trials (EPO, N = 344 patients, JCO Sep 27, 2004
[Epub ahead of print]; DARB N = 320 patients, JNCI 2002
94:1211–20; abstract 981 Eur J Cancer 2001 37, Suppl 6: 264).
Effectiveness was based on the red blood cell transfusion rate
between Week 5 and the end of Week 12 and was standardized
as the difference in transfusion rates between the active drug 
and the respective placebo, divided by the transfusion rate for
the placebo. Estimated costs were presented in 2004 USD and
included drug, physician services, transfusions, laboratory, and
patient opportunity costs. Cost-effectiveness was calculated as
average cost divided by transfusion effectiveness. Threshold
analysis was conducted by ﬁnding the break even point at which
EPO and DARB have the same total cost and cost-effectiveness
ratio, respectively. RESULTS: Estimated total cost over 12 weeks
was $7,618 for EPO and $10,857 for DARB, with drug cost rep-
resenting 85% and 89% for EPO and DARB, respectively. Rel-
ative to placebo, the standardized transfusion effectiveness was
65% for EPO and 48% for DARB, resulting in an average cost
effectiveness ratio of $117 for EPO and $226 for DARB. A 33%
(or 54%) reduction in DARB dose or price would be needed to
equalize the total cost (or cost-effectiveness ratio) with that of
EPO. CONCLUSIONS: Drug cost was determined to be the key
driver of total cost. In addition, this analysis found EPO to be
more effective in reducing blood transfusion requirements and
less costly, and hence the dominant alternative compared to
DARB for the treatment of CIA.
CN2
VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN
VERSUS CISPLATIN ALONE IN THE TREATMENT OF
MALIGNANT PLEURAL MESOTHELIOMA
Davey P1, Cordony A1, Rajan N2,Arora B2, Pavlakis N3
1Medical Technology Assessment Group Pty Ltd, Sydney, NSW,
Australia; 2Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia; 3Royal
North Shore Hospital, Sydney, NSW, Australia
OBJECTIVES: To determine the value-for-money offered by
pemetrexed (Alimta) plus cisplatin therapy for patients with
malignant pleural mesothelioma (MPM), relative to cisplatin
monotherapy, in Australia. MPM is an uncommon, locally inva-
sive and rapidly fatal malignancy. There is currently no other
drug reimbursed by the Australian National Formulary speciﬁ-
cally for the treatment of mesothelioma. METHODS: A 
comprehensive literature search revealed one randomised head-
to-head trial of pemetrexed plus cisplatin therapy versus cisplatin
monotherapy (N = 448), by Vogelzang et al. (2003). Median 
survival for the intention-to-treat (ITT) population was 12.1
months for the pemetrexed plus cisplatin arm versus 9.3 months
for the cisplatin arm (hazard ratio = 0.77, p = 0.020). Although
there was greater toxicity with the combination regimen, quality
of life was not negatively impacted. Mean survival time for each
treatment arm was estimated from Kaplan-Meier survival curves.
Resource use was applied as per the trial and costed accordingly.
Study drug utilisation, concomitant medications, supplementary
medication (dexamethasone, folic acid, and vitamin B12), post-
study chemotherapy, and care for serious and treatment-emer-
gent adverse events were costed. RESULTS: Patients received a
mean of 4.7 treatment cycles in the pemetrexed plus cisplatin
arm, and 4.0 cycles in the cisplatin monotherapy arm. The com-
bination therapy required more supportive care for toxicities.
